Handelsavisen
prelaunch
Companies Health Care UG.CD
UG
UG.CD Pharmaceuticals

Upside Gold Corp

$1,60
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
ROE
-50,5 %
Net margin
Debt / equity
0,00
Beta
52w range
Volume
45
Day range
$6,86–$7,05
Prev close
$7,02
Open
Next earnings
2026-07-28
Ex-dividend
TR 1Y
About

Upside Gold Corp is a diversified mining company engaged in the exploration and development of mineral resources, primarily in the basic materials sector.

Business. Upside Gold Corp (UG.CD) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm operates within the Health Care sector, specifically focusing on the Pharmaceuticals industry. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.

Classification99 %
SectorHealth Care
Industry groupPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsQ2 2026 earnings (expected)2026-07-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-50,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning UG.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,5 %
    Communication Services+2,2 %−5,5 %+1,5 %
    Energy+0,9 %+5,2 %+0,1 %
    Health Care · THIS SECTOR+0,7 %−0,8 %−0,1 %
    Information Technology+0,2 %+8,1 %−0,5 %
    Consumer Discretionary+0,2 %+8,7 %−0,6 %
    Financials−0,3 %−2,8 %−1,0 %
    Consumer Staples−0,6 %+2,2 %−1,3 %
    Real Estate−0,7 %+10,9 %−1,4 %
    Industrials−1,1 %−0,3 %−1,9 %
    Utilities−1,9 %+28,2 %−2,6 %

    Developing storylines

    No tracked sagas currently linked to UG.CD. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-07-27 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ2 2026 earnings (expected)2026-07-28 · estimated
    • Macro
    • Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Upside Gold Corp (UG.CD) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm operates within the Health Care sector, specifically focusing on the Pharmaceuticals industry. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.

    Classification99 %
    SectorHealth Care
    Industry groupPharmaceuticals
    AI synthesis
    GENERATED

    Upside Gold Corp has a capital structure characterized by a debt-to-equity ratio of 0.0, indicating no long-term debt obligations. The company's liquidity position is reflected in a current ratio of 19.94, suggesting strong short-term liquidity. However, the company's operating cash flow is reported at 0.0, which may indicate challenges in generating cash from operations.

    In terms of profitability, the company reported a net income of -381,650.0 and an operating income of -381,650.0, both indicating a loss for the period. The return on equity is -0.5054, and the return on assets is -0.48, both of which are significantly below the industry median for diversified mining companies.

    The company's revenue concentration is not explicitly detailed in the provided data, but the absence of segment-specific revenue data suggests that the company may not have disclosed detailed geographic or product-based revenue breakdowns. This lack of detail may obscure the extent of geographic or product diversification.

    The company's growth trajectory is not clearly defined in the provided data, as there are no specific numeric deltas or revenue history provided for the current or next fiscal year. The absence of such data makes it difficult to assess the company's growth potential or direction.

    The risk assessment indicates a low level of liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's dilution potential is also assessed as low, and no adjustments have been applied to the valuation metrics.

    Recent events, such as filings or transcripts, are not detailed in the provided data, which limits the ability to assess the company's recent performance or strategic direction.

    Key takeaways
    • Upside Gold Corp has a strong liquidity position with a current ratio of 19.94, but it is not generating positive operating cash flow.
    • The company is currently reporting a net loss, with a return on equity of -0.5054 and a return on assets of -0.48, both below industry medians.
    • The company's capital structure is free of long-term debt, which reduces financial leverage risk.
    • There is no immediate liquidity or dilution risk, as indicated by the risk assessment.
    • The company's growth trajectory and revenue concentration are not clearly defined in the provided data.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $1,60
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $755.2k
    Net cash
    Current ratio
    19.9
    Debt / equity
    0.0
    ROA
    -48.0%
    ROE
    -50.5%
    Cash conversion
    0.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryPharmaceuticals695,2B node revenueJNJ 13,6%LLY 9,4%MRK 9,3%PFE 9,0%ABBV 8,8%AZN 8,4%BMY 6,9%GSK 6,2%Other 28,3%
    Source: company disclosures · own-taxonomy revenue-covered set · attribution: collision-suspect (indicative)UG 0,0% · rank #59 of 68

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs UG · multiples and returns
    JN
    JNJ
    Johnson & Johnson
    $259,27
    634,0B USD
    P/E
    23,5x
    +8,1 vs self
    Div yield
    2,0 %
    -4,9 vs self
    ROE
    33,0 %
    +14,3 vs self
    LL
    LLY
    ELI LILLY AND COMPANY
    $1 198,27
    1,07T USD
    P/E
    133,8x
    +118,4 vs self
    Div yield
    0,5 %
    -6,3 vs self
    ROE
    23,7 %
    +5,0 vs self
    MR
    MRK
    MERCK & CO., INC.
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    PF
    PFE
    Pfizer Inc
    $24,55
    140,7B USD
    P/E
    54,9x
    +39,5 vs self
    Div yield
    7,2 %
    +0,4 vs self
    ROE
    3,0 %
    -15,8 vs self
    AB
    ABBV
    Abbvie Inc
    $259,35
    460,1B USD
    P/E
    106,8x
    +91,4 vs self
    Div yield
    2,6 %
    -4,2 vs self
    ROE
    -63,5 %
    -82,2 vs self
    AZ
    AZN
    AZN.L
    $171,10
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    BM
    BMY
    Bristol-myers Squibb Co
    $62,09
    127,1B USD
    P/E
    16,3x
    +0,9 vs self
    Div yield
    4,4 %
    -2,4 vs self
    ROE
    35,1 %
    +16,4 vs self
    GS
    GSK
    Gsk Plc-spon Adr
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE-50,5 %Bottom quartile
    D/E0,00Above P75
    Cash Conv0,00Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • Upside Gold Corp Market data — financials · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    UG.CDCanonical
    — · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -43.3%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -35.2%Derived (calculated)
    • Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -5.5%Derived (calculated)
    • Current ratio (FY 2025-12-31): 7.31xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.17xDerived (calculated)
    • Return on assets (FY 2025-12-31): 16.1%Derived (calculated)
    • Return on equity (FY 2025-12-31): 18.7%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): -86.4%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -33.3%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -38.5%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -35.2%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -2.0%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -5.5%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -5.0%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 1.5%Derived (calculated)
    • Pre-tax income (annual): USD 2.64MSEC XBRL filing
    • Total assets (annual): USD 13.11MSEC XBRL filing
    • Current liabilities (annual): USD 1.67MSEC XBRL filing
    • Shares outstanding (annual): 4.59MSEC XBRL filing
    • Current assets (annual): USD 12.2MSEC XBRL filing
    • Total liabilities (annual): USD 1.88MSEC XBRL filing
    • R&D expense (annual): USD 463.64KSEC XBRL filing
    • Net income (annual): USD 2.11MSEC XBRL filing
    • Cost of revenue (annual): USD 5.4MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-07-28EVENTUpcomingQ2 2026 earnings (expected) estimated date
    2026-05-15FILINGFORM 8-K →
    2026-05-12FILINGFORM 10-Q →
    2026-05-08FILINGFORM 8-K →
    2026-04-06FILINGFORM DEF 14A →
    2026-03-27FILINGFORM 10-K →
    2026-03-27FILINGFORM 8-K →
    2026-01-29FILINGFORM 8-K →
    2026-01-21 00:00 UTCINSIDER1 insider transaction — 2026-01
    2026-01-21INSIDERGLOBUS KENNETH H transacted 7.5k sh — Director
    2025-11-06FILINGFORM 10-Q →
    2025-11-06FILINGFORM 8-K →
    2025-08-08FILINGFORM 10-Q →
    2025-08-08FILINGFORM 8-K →
    2025-07-15FILINGFORM 8-K →
    2021-02-19 00:00 UTCINSIDER1 insider transaction — 2021-02
    2020-03-05 00:00 UTCINSIDER1 insider transaction — 2020-03
    2019-05-20 00:00 UTCINSIDER1 insider transaction — 2019-05
    2018-09-24 00:00 UTCINSIDER1 insider transaction — 2018-09
    2017-08-01 00:00 UTCINSIDER1 insider transaction — 2017-08
    2017-07-05 00:00 UTCINSIDER1 insider transaction — 2017-07
    2016-12-09 00:00 UTCINSIDER1 insider transaction — 2016-12
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-07-27 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage